Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 6

    1.

    No increased risk of hypoglycaemic episodes during 48 h of subcutaneous glucagon-like-peptide-1 administration in fasting healthy subjects.

    Lerche S, Soendergaard L, Rungby J, Moeller N, Holst JJ, Schmitz OE, Brock B.

    Clin Endocrinol (Oxf). 2009 Oct;71(4):500-6. Epub 2008 Dec 15.PMID: 19094067 [PubMed - in process]Related articles

    2.

    Muscle RING-finger protein-1 (MuRF1) as a connector of muscle energy metabolism and protein synthesis.

    Koyama S, Hata S, Witt CC, Ono Y, Lerche S, Ojima K, Chiba T, Doi N, Kitamura F, Tanaka K, Abe K, Witt SH, Rybin V, Gasch A, Franz T, Labeit S, Sorimachi H.

    J Mol Biol. 2008 Mar 7;376(5):1224-36. Epub 2007 Nov 22.PMID: 18222470 [PubMed - indexed for MEDLINE]Related articles

    3.

    Cooperative control of striated muscle mass and metabolism by MuRF1 and MuRF2.

    Witt CC, Witt SH, Lerche S, Labeit D, Back W, Labeit S.

    EMBO J. 2008 Jan 23;27(2):350-60. Epub 2007 Dec 20.PMID: 18157088 [PubMed - indexed for MEDLINE]Related articlesFree article

    4.

    Glucagon-like peptide-1 inhibits blood-brain glucose transfer in humans.

    Lerche S, Brock B, Rungby J, Bøtker HE, Møller N, Rodell A, Bibby BM, Holst JJ, Schmitz O, Gjedde A.

    Diabetes. 2008 Feb;57(2):325-31. Epub 2007 Nov 8.PMID: 17991759 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    Hearing impairment after prolonged dihydrostreptomycin treatment of surgical tuberculosis.

    Lerche S.

    Scand J Respir Dis. 1972;53(1):27-34. No abstract available. PMID: 4115288 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Find related data

    Search details

    » See more...